Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV

Clinical Pharmacokinetics
R BrunoG Filice

Abstract

To compare the plasma pharmacokinetics of lamivudine 150mg twice daily and 300mg once daily in patients with HIV-1 infection. Nonblind, sequential, pharmacokinetic study. 13 patients with HIV-1 infection (median age 36 years). Patients were tested during twice daily and then once daily regimens of lamivudine. In both regimens, the total daily dose of lamivudine was identical (300 mg/day). Blood samples for pharmacokinetic analysis were taken over a 12-hour period after > or =7 days of twice daily administration, and again over a 24-hour period after 7 days of once daily administration,. 12 patients completed the study. Lamivudine pharmacokinetic parameters (mean +/- SD) after administration of 150mg twice daily were: peak plasma concentration (Cmax) 2077+/-816 microg/L; trough plasma concentration (Cmin) 332+/-219 microg/L; elimination half-life (t 1/2beta) 6.1+/-1.9h; time to Cmax (t(max)) 1.6+/-0.7h; average concentration over the dosage interval (Cav) 711+/-269 microg/L; and area under the concentration-time curve (AUC) over 2 dosage intervals (24h) 17085+/-6464 microg x h/L. Corresponding values after administration of 300mg once daily were: Cmax 3461+/-854 microg/L; Cmin 146+/-87 microg/L; t1/2 7.9+/-3.4h; t(max) 2.2+/-1.3...Continue Reading

Citations

Mar 6, 2010·Advances in Therapy·Chad J AchenbachRobert L Murphy
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Edwin DeJesusUNKNOWN EPV20001 International Study Team
Sep 26, 2007·Antimicrobial Agents and Chemotherapy·Adriana H TremouletUNKNOWN Pediatric AIDS Clinical Trials Group
May 18, 2011·Antimicrobial Agents and Chemotherapy·Naïm BouazzaSaik Urien
Mar 18, 2010·Therapeutics and Clinical Risk Management·Geetha SivasubramanianRodger D Macarthur
Nov 11, 2003·Clinical Pharmacokinetics·Anne-Marie TaburetJean-Michel Molina
Aug 22, 2003·Journal of the American Academy of Nurse Practitioners·Peter J Piliero, Joseph P Colagreco
Dec 20, 2011·Journal of Clinical Pharmacology·Adriana H TremouletEdmund V Capparelli
Apr 23, 2014·British Journal of Clinical Pharmacology·Naïm BouazzaSaik Urien
Jul 27, 2011·Expert Opinion on Pharmacotherapy·Giuliano Rizzardini, Patrizia Zucchi
Dec 8, 2006·Expert Opinion on Pharmacotherapy·Laura Waters, Graeme Moyle
Oct 14, 2004·The Annals of Pharmacotherapy·Peter L Anderson
Mar 3, 2007·Clinical Pharmacology and Therapeutics·D M BurgerR de Groot
Dec 3, 2014·Biosensors & Bioelectronics·Nesrine Abdelrehim El GoharyBoris Mizaikoff
Aug 21, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Peter J Piliero
Jul 2, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·David J BackJohn G Gerber
Jan 11, 2013·The Open AIDS Journal·Winai RatanasuwanPaul J Weidle
Dec 23, 2011·Clinical Pharmacology and Therapeutics·P KasiryeUNKNOWN ARROW Trial Team
Sep 10, 2005·The Journal of Antimicrobial Chemotherapy·F PulidoE Martínez
Feb 24, 2018·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Romina QuerciaDaniel Kuritzkes
Oct 3, 2003·AIDS·Jintanat AnanworanichUNKNOWN Swiss HIV Cohort Study
Oct 12, 2020·Drugs·Andrew MujugiraJessica E Haberer
Feb 24, 2021·AIDS·David MetsuGuillaume Martin-Blondel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.